Adding rivaroxaban to antiplatelet therapy post-ACS; role of vorapaxar in dual antiplatelet therapy; full prescription coverage post-MI improves medication adherence; increased bleeding risk with abciximab plus heparin vs. bivalirudin for PCI in NSTEMI patients.
After taking part in this educational activity, participants should be better able to:
James A. de Lemos, MD, has received speakers’ honoraria from sanofi-aventis—Bristol-Myers Squibb partnership; consulting fees from AstraZeneca; and research grants from Roche Diagnostics.
Sandeep R. Das, MD, MPH, has no relevant relationships to disclose.
Michael C. Kontos, MD, has received honoraria from Astellas and AstraZeneca.
E. Scott Monrad, MD, has no relevant relationships to disclose.
The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine has nothing to disclose relative to this CME activity.
Publishing Staff Disclosures
Suzanne Bujara, Melissa Johnson, and Anne Bardsley, Haymarket Medical Education, have nothing to disclose with regard to commercial support.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Albert Einstein College of Medicine of Yeshiva University, Daiichi Sankyo, Inc., Lilly USA, LLC, and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine of Yeshiva University, Daiichi Sankyo, Inc., Lilly USA, LLC, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
If you have any questions relating to the accreditation of this activity, please contact Mildred Adighiuzor at 718-920-6674.
Cardiologists, Primary Care Physicians
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University and Haymarket Medical Education. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein Designates this enduring material for a maximum of 2.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To obtain credit, a score of 70% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.